Recombinant Human VEGF165 Protein, His Tag, 50µg

Background
VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

Source
Recombinant Human VEGF165, His Tag (VE5-H5248) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4 ).
Predicted N-terminus: His

Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus. The protein has a calculated MW of 21.1 kDa. The protein migrates as 25-27 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Angiogenic Modification of Microfibrous Polycaprolactone by pCMV-VEGF165 Plasmid Promotes Local Vascular Growth after Implantation in Rats"
Klabukov, Balyasin, Krasilnikova et al
Int J Mol Sci (2023) 24 (2)
(2) "Heparin-Induced Changes of Vascular Endothelial Growth Factor (VEGF165) Structure"
Nemashkalova, Shevelyova, Machulin et al
Biomolecules (2023) 13 (1)
(3) "Molecular mechanism of binding between a therapeutic RNA aptamer and its protein target VEGF: A molecular dynamics study"
Kalathingal, Rhee
J Comput Chem (2023)
Showing 1-3 of 1885 papers.